Biocon’s $3.3bn Biosimilars Big Leap Also Marks Viatris’ 'Smart' Exit, Albeit Toehold

Biocon seals milestone deal to acquire Viatris’s biosimilars assets for up to $3.3bn, accelerating its direct commercialization push across key markets and also bringing with it rights to key in-licensed therapies, including biosimilar adalimumab, and an option to acquire the US firm’s rights for biosimilar aflibercept.